3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
9
Neurofibrosarcoma
4
Liposarcoma
3
Sarcoma, Alveolar Soft Part
2
Multiple Myeloma
2
Wilms Tumor
1
Vascular Neoplasms
1
Solitary Fibrous Tumors
1
Smooth Muscle Tumor
1
Sarcoma, Ewing
1
Sarcoma, Endometrial Stromal
1
Sarcoma, Clear Cell
1
Rhabdoid Tumor
1
Primary Myelofibrosis
1
Osteosarcoma
1
Nerve Sheath Neoplasms
1
Neoplasms, Adipose Tissue
1
Neoplasm Metastasis
1
Myoepithelioma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Liposarcoma, Myxoid
1
Leiomyosarcoma
1
Histiocytoma, Angiomatoid Fibrous
1
Hemangiosarcoma
1
Hemangioendothelioma, Epithelioid
1
Granuloma, Plasma Cell
1
Granular Cell Tumor
1
Glomus Tumor
1
Gliosarcoma
1
Interventions
apatinib
4
Ifosfamide
2
Filgrastim
2
Etoposide
2
selinexor
1
glucarpidase
1
camrelizumab
1
Vincristine
1
Radiotherapy
1
Procarbazine
1
Pharmaceutical Preparations
1
Methotrexate
1
Lomustine
1
Imatinib Mesylate
1
Genetic Therapy
1
Fibroblast Growth Factor 7
1
Drug Combinations
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Drug-Related Side Effects and Adverse Reactions
×
selinexor
×
Sarcoma
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled